ArcticZymes Q2 2025 slides: Biomanufacturing growth offsets Molecular Tools decline

ArcticZymes Technologies (AZT) reported a significant Q2 2025 recovery, with revenue up 5% to 28.9M NOK and EBITDA increasing 50% to 3.9M NOK, rebounding from a challenging Q1. Growth was primarily driven by exceptional 52% year-over-year performance in its Biomanufacturing segment, bolstered by M-SAN HQ and the launch of GMP-grade M-SAN. Conversely, the Molecular Tools segment saw a 40% revenue decline due to a key customer's temporary absence, though a recovery is anticipated as the customer has returned. AZT maintains a strong cash position and expects continued Biomanufacturing momentum and a Molecular Tools rebound in H2 2025.

Analysis

ArcticZymes Technologies (AZT) demonstrated a significant operational recovery in its Q2 2025 results, rebounding from a challenging first quarter. The company reported a 5% year-over-year revenue increase to 28.9 million NOK and a substantial 50% rise in EBITDA to 3.9 million NOK, which expanded the EBITDA margin from 9.5% to 13.5%. This performance masks a stark divergence between its two primary business segments. The Biomanufacturing division was the clear growth engine, with sales surging 52% year-over-year to 18.1 million NOK, now constituting approximately 67% of total product sales. This strength was driven by the M-SAN HQ product line and critically supported by the recent launch of a GMP-grade M-SAN, which opens access to the highly regulated late-stage and commercial biomanufacturing markets. Conversely, the Molecular Tools segment experienced a significant 40% revenue decline to 8.7 million NOK. However, management attributes this weakness primarily to the temporary absence of a single key customer who has since resumed ordering, suggesting the downturn may be transient. The company's financial foundation remains robust, with a debt-free balance sheet, a cash position of 240 million NOK, and gross margins consistently above 90%, providing substantial flexibility for its stated long-term M&A ambitions and strategic growth initiatives.

Key Decisions for Investors

• Investors should weigh the powerful 52% growth in the Biomanufacturing segment, viewing the new GMP-grade M-SAN product as a key catalyst for accessing more valuable, long-term contracts in advanced therapies.
• The 40% decline in the Molecular Tools segment requires close monitoring, but the confirmation of a key customer's return could signal a swift rebound in H2 2025, potentially making the current weakness a non-recurring event.
• Consider the company's strong financial health, including a 240 million NOK cash reserve and no debt, as a significant de-risking factor that provides resilience and optionality for strategic investments or M&A to accelerate growth.